These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38014622)

  • 1. Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial.
    Yamashita T; Nakano Y; Sasaki R; Tadokoro K; Omote Y; Yunoki T; Kawahara Y; Matsumoto N; Taira Y; Matsuoka C; Morihara R; Abe K
    Cell Transplant; 2023; 32():9636897231214370. PubMed ID: 38014622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
    Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
    Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of intravenous administration of human Muse cells with deficit amelioration in a rat model of spinal cord injury.
    Kajitani T; Endo T; Iwabuchi N; Inoue T; Takahashi Y; Abe T; Niizuma K; Tominaga T
    J Neurosurg Spine; 2021 Apr; 34(4):648-655. PubMed ID: 33385996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
    Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
    BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
    Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial.
    Koda M; Imagama S; Nakashima H; Ito S; Segi N; Ouchida J; Suda K; Harmon Matsumoto S; Komatsu M; Endo T; Suzuki S; Inami S; Ueda H; Miyagi M; Inoue G; Takaso M; Nagata K; Yamada H; Kamei N; Nakamae T; Suzuki H; Nishida N; Funaba M; Kumagai G; Furuya T; Yamato Y; Funayama T; Takahashi H; Yamazaki M
    Stem Cell Res Ther; 2024 Aug; 15(1):259. PubMed ID: 39135172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous Administration of Human Muse Cells Ameliorates Deficits in a Rat Model of Subacute Spinal Cord Injury.
    Takahashi Y; Kajitani T; Endo T; Nakayashiki A; Inoue T; Niizuma K; Tominaga T
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
    Imamura K; Izumi Y; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Egawa N; Ayaki T; Oki R; Fujita K; Uozumi R; Morinaga A; Hirohashi T; Fujii Y; Yamamoto T; Tatebe H; Tokuda T; Takahashi N; Morita S; Takahashi R; Inoue H
    EClinicalMedicine; 2022 Nov; 53():101707. PubMed ID: 36467452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
    Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
    Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke.
    Niizuma K; Osawa SI; Endo H; Izumi SI; Ataka K; Hirakawa A; Iwano M; Tominaga T
    J Cereb Blood Flow Metab; 2023 Dec; 43(12):2029-2039. PubMed ID: 37756573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis.
    Henderson RD; Agosti JM; McCombe PA; Thorpe K; Heggie S; Heshmat S; Appleby MW; Ziegelaar BW; Crowe DT; Redlich GL
    Medicine (Baltimore); 2021 Oct; 100(42):e27421. PubMed ID: 34678870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.
    Camu W; Mickunas M; Veyrune JL; Payan C; Garlanda C; Locati M; Juntas-Morales R; Pageot N; Malaspina A; Andreasson U; Kirby J; Suehs C; Saker S; Masseguin C; De Vos J; Zetterberg H; Shaw PJ; Al-Chalabi A; Leigh PN; Tree T; Bensimon G
    EBioMedicine; 2020 Sep; 59():102844. PubMed ID: 32651161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).
    Salamone P; Fuda G; Casale F; Marrali G; Lunetta C; Caponnetto C; Mazzini L; La Bella V; Mandrioli J; Simone IL; Moglia C; Calvo A; Tarella C; Chio A;
    BMJ Open; 2020 Mar; 10(3):e034049. PubMed ID: 32209625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.
    Stommel EW; Cohen JA; Fadul CE; Cogbill CH; Graber DJ; Kingman L; Mackenzie T; Channon Smith JY; Harris BT
    Amyotroph Lateral Scler; 2009; 10(5-6):393-404. PubMed ID: 19922130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
    Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).
    Yoshino H; Kimura A
    Amyotroph Lateral Scler; 2006 Dec; 7(4):241-5. PubMed ID: 17127563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).
    Vucic S; Ryder J; Mekhael L; Rd H; Mathers S; Needham M; Dw S; Mc K;
    Medicine (Baltimore); 2020 Feb; 99(6):e18904. PubMed ID: 32028398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
    Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
    JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.